| Autor: |
Shah, Nemil, Zhai, Guihua, Knowles, Joseph, Stockard, Cecil, Grizzle, William, Fineberg, Naomi, Zhou, Tong, Zinn, Kurt, Rosenthal, Eben, Kim, Hyunki |
| Předmět: |
|
| Zdroj: |
Molecular Imaging & Biology; Apr2012, Vol. 14 Issue 2, p237-244, 8p |
| Abstrakt: |
Purpose: The objective of this study is to evaluate the therapeutic response to a novel monoclonal antibody targeting human extracellular matrix metalloproteinase inducer (EMMPRIN) in combination with gemcitabine in a pancreatic-tumor xenograft murine model by sequential 2-deoxy-2-[18F]fluoro- d-glucose (F-FDG) positron emission tomography/computed tomgraphy (PET/CT) imaging. Procedures: Four groups of SCID mice bearing orthotopic pancreatic tumor xenografts were injected with phosphate-buffered saline, gemcitabine (120 mg/kg BW), anti-EMMPRIN antibody (0.2 mg), or combination, respectively, twice weekly for 2 weeks, while F-FDG PET/CT imaging was performed weekly for 3 weeks. Changes in mean standardized uptake value (SUV) of F-FDG and volume of tumors were determined. Results: The tumor SUV change in the group receiving combination therapy was significantly lower than those of the other groups. Tumor-volume changes of groups treated with anti-EMMPRIN monotherapy or combined therapy were significantly lower than that of the control group. Conclusions: These data provide support for clinical studies of anti-EMMPRIN therapy with gemcitabine for pancreatic cancer treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink